Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients

• Published in: Annals of neurology Vol. 87; no. 5; pp. 688 - 699
• Main Authors: Alping, Peter, Askling, Johan, Burman, Joachim, Fink, Katharina, Fogdell‐Hahn, Anna, Gunnarsson, Martin, Hillert, Jan, Langer‐Gould, Annette, Lycke, Jan, Nilsson, Petra, Salzer, Jonatan, Svenningsson, Anders, Vrethem, Magnus, Olsson, Tomas, Piehl, Fredrik, Frisell, Thomas
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 2020; Wiley Subscription Services, Inc
• Subjects: Cancer; Cancer and Oncology; Cancer och onkologi; Clinical Medicine; Comparative studies; Confidence intervals; Health risks; Immunotherapy; Invasiveness; Klinisk medicin; Medical and Health Sciences; Medicin och hälsovetenskap; Monoclonal antibodies; Multiple sclerosis; Neurologi; Neurology; Neurosciences; Neurovetenskaper; Population; Risk; Rituximab; Targeted cancer therapy

Objective Novel, highly effective disease‐modifying therapies have revolutionized multiple sclerosis (MS) care. However, evidence from large comparative studies on important safety outcomes, such as cancer, is still lacking. Methods In this nationwide register‐based cohort study, we linked data from...